Next Article in Journal
Lp-PLA2 Inhibition—The Atherosclerosis Panacea?
Next Article in Special Issue
Combining Biofilm-Controlling Compounds and Antibiotics as a Promising New Way to Control Biofilm Infections
Previous Article in Journal
NSAIDs, Opioids, Cannabinoids and the Control of Pain by the Central Nervous System
Previous Article in Special Issue
Lysostaphin: A Staphylococcal Bacteriolysin with Potential Clinical Applications
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2010, 3(5), 1348-1359;

Health Economics of Antibiotics

Research Centre for Pharmaceutical Care and Pharmaco-economics, Katholieke Universiteit Leuven, O&N 2 P.O. Box 521, Herestraat 49, 3000 Leuven, Belgium
Received: 29 March 2010 / Revised: 19 April 2010 / Accepted: 23 April 2010 / Published: 29 April 2010
(This article belongs to the Special Issue Antibiotics)
Full-Text   |   PDF [200 KB, uploaded 29 April 2010]   |  


Antibiotics have made a significant contribution to improving patient health, but policy makers and health care payers are concerned about the costs of antibiotics in addition to their effectiveness. This paper aims to assess the value of antibiotics by examining incremental cost-utility ratios of antibiotics. Evidence was derived from cost-utility analyses of antibiotics included in the Tufts-New England Center Cost-Effectiveness Analysis Registry through September 2009. The analysis included 85 incremental cost-utility ratios from 23 cost-utility analyses. The findings showed that 38.8% of incremental cost-utility ratios related to dominant antibiotics (i.e., more effective and less costly than the comparator); 45.9% referred to antibiotics that improved effectiveness, but also increased costs; and 15.3% related to dominated antibiotics (i.e., less effective and more costly than the comparator). The median ratio was 748 € per quality-adjusted life year. Using threshold values of 20,000 € per quality-adjusted life year and 50,000 € per quality-adjusted life year, the probability that an antibiotic provides value for money was 64% and 67%, respectively. The current evidence base suggests that the majority of antibiotics provide value for money and that antibiotics can aid decision makers to attain further population health improvements, whilst containing pharmaceutical expenditures. View Full-Text
Keywords: health economics; antibiotics; cost-utility analysis; incremental cost-utility ratio health economics; antibiotics; cost-utility analysis; incremental cost-utility ratio

Figure 1

This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

MDPI and ACS Style

Simoens, S. Health Economics of Antibiotics. Pharmaceuticals 2010, 3, 1348-1359.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top